Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

58.44
-1.5600-2.60%
Post-market: 58.28-0.1647-0.28%19:46 EDT
Volume:2.08M
Turnover:122.59M
Market Cap:11.29B
PE:154.20
High:60.16
Open:59.81
Low:58.39
Close:60.00
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.11
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.79
PE(LYR):32.47

Loading ...

BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia

TIPRANKS
·
Jun 16

BioMarin says VOXZOGO lifts height SDS 0.72 over three years in hypochondroplasia study at ENDO 2026

Reuters
·
Jun 16

Is VOXZOGO’s Hypochondroplasia Data and Amicus Deal Reshaping the Investment Case for BioMarin (BMRN)?

Simply Wall St.
·
Jun 10

BioMarin shareholders approved 7,650,000-share increase to 2017 equity plan at annual meeting

Reuters
·
Jun 05

A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Strength

Simply Wall St.
·
Jun 04

BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim

TIPRANKS
·
Jun 03

Centene, Deckers and 14 Other 'Dividend Hopefuls' -- Barrons.com

Dow Jones
·
Jun 02

Capricor names Michael Maurer chief commercial officer

Reuters
·
May 29

BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
May 25

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 24

BioMarin Pharmaceutical Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
May 23

BioMarin price target lowered to $111 from $116 at Canaccord

TIPRANKS
·
May 22

BioMarin's drug shows significant growth gains in children in late-stage trial

Reuters
·
May 21

BioMarin Says Phase 3 Study of Voxzogo Shows Patient Improvements

Dow Jones
·
May 21

BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial

TIPRANKS
·
May 21

BioMarin plans FDA filing in Q3 2026 for Voxzogo in hypochondroplasia

Reuters
·
May 21

Biomarin Pharmaceutical Inc: Safety Findings Consistent With Established Profile in Achondroplasia

THOMSON REUTERS
·
May 21

Biomarin Pharmaceutical Inc - No New Safety Signals Identified in Phase 3 Study

THOMSON REUTERS
·
May 21

Biomarin Pharmaceutical Inc - Phase 3 Study Shows 2.33 Cm/Yr Increase in Annualized Growth Velocity at Week 52

THOMSON REUTERS
·
May 21

Biomarin Announces Positive Phase 3 Pivotal Study Results for Voxzogo® (Vosoritide) in Children With Hypochondroplasia

THOMSON REUTERS
·
May 21